EMA-FDA-PMDA action + Podcasts (CDD, Pew) + NEJM on non-inferiority

Dear All: Several updates today, all on the theme of good things to know or share!

First, EMA, FDA, and PMDA are continuing to meet and have released a summary of their third tripartite meetingThe key message is alignment: alignment on trial designs for key indications, alignment on pediatric programs, and alignment on single global development programs! This is excellent to see and I look forward to hearing more about this during the 2018 meetings.

Second, CDD (Collaborative Drug Discovery) has released a podcast by Lynn Silver and Johannes Zuegg in which they survey ways to think about finding molecules for Gram-negatives that both penetrate and have reliable activity. CDD will also host a webinar on 13 Dec 2017 on BMGF’s TB Drug Accelerator program.

Third, a recent paper in NEJM by Mauri & D’Agostino provides a good survey of non-inferiority trial designs. you haven’t already done so, read as well the May 2017 Rex, Talbot, et al. paper in CID on non-inferiority designs specifically for antimicrobial agents. If you’re going to work in this area, you need an in-depth understanding of strengths and weaknesses of these trials and these papers provide the background you need.

Finally, our colleagues at Pew Trust have released a variety of materials that you may find useful personally or to share. These include a podcast, two Q&A documents, and a trio of patient vignettes. All these materials are suitable for helping tell the story of AMR to interested colleagues — the patient vignettes are brief (~5 minutes) and especially compelling.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

How economists (and Finance Ministers) think…

Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Scroll to Top